The Effect of Glutamatergic Modulation on Cocaine Self-administration

NCT02596022 | Completed Phase 2 Results

• 1 other identifier: 6716
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

Repeated drug consumption may progress to problematic use by triggering neuroplastic adaptations that attenuate sensitivity to natural rewards while increasing reactivity to craving and drug cues. Converging evidence suggests that glutamate modulation may work to correct these adaptations and rapidly restore motivation for delayed non-drug rewards relative to immediate drug use. Using an established laboratory model aimed at evaluating behavioral shifts in the salience of cocaine now vs. money later, the investigators will test the effect of CI-581a on cocaine self-administration as compared to the active control.

Conditions

Cocaine Dependence

Outcome Measures

Primary Outcomes (1)

• Number of Choices to Self-administer Cocaine (Out of 5 Choices)

  Participants provided 5 choices (cocaine 25 mg now vs. $11 later), with choices spaces 15 minutes apart over the course of the session.

  24 hours post-infusion

Study Arms (2)

CI-581a

EXPERIMENTAL

Administration of CI-581a followed 2 weeks later by CI-581b

Drug: CI-581a; Drug: CI-581b

CI-581b

ACTIVE COMPARATOR

Administration of CI-581b followed 2 weeks later by CI-581a

Drug: CI-581a; Drug: CI-581b

Interventions

CI-581a DRUG

a 50 minute infusion 24 hours prior to cocaine self-administration session

CI-581a; CI-581b

CI-581b DRUG

a 50 minute infusion 24 hours prior to cocaine self-administration session

CI-581a; CI-581b

Eligibility Criteria

• Age: 21 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Active cocaine dependence with at least 8 days of use or at least 4 binges of large amounts (\>$200/occasion) over the past 30 days, and displaying at least one positive utox during screening
• Physically healthy
• No adverse reactions to study medications
• years of age
• Capacity to consent and comply with study procedures, including sufficient proficiency in English
• Not seeking treatment

You may not qualify if:

• Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder with HAMD score \> 12.
• Physiological dependence on another substance, such as alcohol, opioids, or benzodiazepines, excluding caffeine, nicotine, and cannabis
• Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders
• Current suicide risk or a history of suicide attempt within the past year
• Pregnant or interested in becoming pregnant during the study period
• Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
• Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), WBC \< 3.5, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if PT/PTT is normal), renal failure (creat \> 2, BUN \>40), or untreated diabetes
• Previous history of ketamine or midazolam misuse or abuse, and a history of an adverse reaction/experience with prior exposure to cocaine, ketamine or midazolam
• Recent history of significant violence (past 2 years)
• Abnormal pseudocholinesterase level
• First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS)
• BMI \> 35, or a history of documented obstructive sleep apnea
• On psychotropic or other medications whose effect could be disrupted by participation in the study

Sponsors & Collaborators

• New York State Psychiatric Institute: lead

MeSH Terms

Conditions

Cocaine-Related Disorders

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Results Point of Contact

• Title: Linda Sherman
• Organization: NYSPI

lsherma@nyspi.columbia.edu

6467747158

Study Officials

• Elias Dakwar, MD

  Columbia College of Physicians and Surgeons

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: research psychiatrist

Study Record Dates

• First Submitted: November 2, 2015
• First Posted: November 4, 2015
• Study Start: June 1, 2013
• Primary Completion: June 1, 2015
• Study Completion: July 1, 2015
• Last Updated: June 15, 2018
• Results First Posted: October 17, 2017

Record last verified: 2018-06